Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

James L. Rubenstein, MD, PhD, Paul Formaker, Xiaomin Wang, PhD, Nianhang Chen, PhD, Michael Seider, MD, Pamela Munster, MD, Bertil Damato, MD, PhD

Blood (2014) 124 (21): 4470.

https://doi.org/10.1182/blood.V124.21.4470.4470

Published: 2014

Journal Articles

Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma

Nianhang Chen, PhD, Ene Ette, PhD, Simon Zhou, PhD, Daniel Weiss, MD, Maria Palmisano, MD

Blood (2013) 122 (21): 3234.

https://doi.org/10.1182/blood.V122.21.3234.3234

Published: 2013

Journal Articles

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Nianhang Chen, PhD, Daniel Weiss, MD, Josephine Reyes, DVM, Liangang Liu, PhD, Claudia Kasserra, PhD, Xiaomin Wang, PhD, Simon Zhou, PhD, Gondi Kumar, PhD, Lilia Weiss, MD, Maria Palmisano, MD

Blood (2013) 122 (21): 5395.

https://doi.org/10.1182/blood.V122.21.5395.5395

Published: 2013

Journal Articles

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Nianhang Chen, PhD, Dao-bin Zhou, MD, Li Yu, Jay Mei, MD, PhD, Liangang Liu, Xiaomin Wang, Honeylet Wortman-Vayn, Jian Hou, MD, PhD

Blood (2012) 120 (21): 5046.

https://doi.org/10.1182/blood.V120.21.5046.5046

Published: 2012

Journal Articles

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Alan F. List, MD, Jeffrey E. Lancet, MD, Magda Melchert, MD, Hussein Saba, MD, Richard Lush, PhD, Jian Yu, PhD, Nianhang Chen, PhD, Michele Schmidt, RN, Robert Knight, MD

Blood (2007) 110 (11): 4626.

https://doi.org/10.1182/blood.V110.11.4626.4626

Published: 2007

NARROW

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Email alerts

ASH Publications

American Society of Hematology

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only